Literature DB >> 21191524

Hyperprolactinemia associated with risperidone: a case report and review of literature.

Ahmed Aboraya1, Jennifer E Fullen, Barbara L Ponieman, Eugene H Makela, Melissa Latocha.   

Abstract

This case report describes a 19-year-old Caucasian woman who presented to a state psychiatric facility with symptoms of depression and auditory hallucinations. She was diagnosed with schizoaffective disorder, depressed type, and was treated with risperidone and sertraline. Soon after initiation of drug therapy, the patient developed galactorrhea and dysmenorrhea, and her prolactin level was 171.6ng/mL (normal level 2.8-29.2ng/mL in adult women). Upon discontinuation of risperidone, the prolactin level dropped to 17.2ng/mL within one week. The patient was treated with quetiapine and titrated up to 800mg daily. Repeated prolactin levels continued to be normal during treatment with quetiapine. This case report and others from literature suggest that risperidone is associated with hyperprolactinemia, and that quetiapine is less likely to be associated with hyperprolactinemia.

Entities:  

Year:  2004        PMID: 21191524      PMCID: PMC3010960     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  34 in total

1.  Risperidone-induced galactorrhea.

Authors:  S Schreiber; R H Segman
Journal:  Psychopharmacology (Berl)       Date:  1997-04       Impact factor: 4.530

2.  Prolactin levels and adverse events in patients treated with risperidone.

Authors:  D L Kleinberg; J M Davis; R de Coster; B Van Baelen; M Brecher
Journal:  J Clin Psychopharmacol       Date:  1999-02       Impact factor: 3.153

3.  The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.

Authors:  H Y Meltzer; S Matsubara; J C Lee
Journal:  Psychopharmacol Bull       Date:  1989

4.  Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients.

Authors:  M Markianos; J Hatzimanolis; L Lykouras
Journal:  Eur Neuropsychopharmacol       Date:  1999-12       Impact factor: 4.600

5.  Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Authors:  J G Small; S R Hirsch; L A Arvanitis; B G Miller; C G Link
Journal:  Arch Gen Psychiatry       Date:  1997-06

6.  Prolactin responses to neuroleptics in normal and schizophrenic subjects.

Authors:  P H Gruen; E J Sachar; G Langer; N Altman; M Leifer; A Frantz; F S Halpern
Journal:  Arch Gen Psychiatry       Date:  1978-01

7.  Pattern of development of hyperprolactinemia after initiation of haloperidol therapy.

Authors:  M Spitzer; R Sajjad; F Benjamin
Journal:  Obstet Gynecol       Date:  1998-05       Impact factor: 7.661

8.  Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects.

Authors:  Uriel Halbreich; Linda S Kahn
Journal:  J Psychiatr Pract       Date:  2003-09       Impact factor: 1.325

9.  An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

Authors:  D C Goff; T Posever; L Herz; J Simmons; N Kletti; K Lapierre; K D Wilner; C G Law; G N Ko
Journal:  J Clin Psychopharmacol       Date:  1998-08       Impact factor: 3.153

10.  Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.

Authors:  V A Rao; M Bishop; A Coppen
Journal:  Br J Psychiatry       Date:  1980-12       Impact factor: 9.319

View more
  1 in total

1.  Associated mortality risk of atypical antipsychotic medication in individuals with dementia.

Authors:  Peter Phiri; Tomas Engelthaler; Hannah Carr; Gayathri Delanerolle; Clive Holmes; Shanaya Rathod
Journal:  World J Psychiatry       Date:  2022-02-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.